Cost-effectiveness of bazedoxifene and raloxifene for the treatment of postmenopausal osteoporosis in Europe

Trial Profile

Cost-effectiveness of bazedoxifene and raloxifene for the treatment of postmenopausal osteoporosis in Europe

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Apr 2012

At a glance

  • Drugs Bazedoxifene (Primary) ; Raloxifene (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2012 New trial record
    • 24 Mar 2012 Results presented at the 2012 IOF World Congress on Osteoporosis and 11th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top